• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Dulaglutide improves glycemic control for youth with type 2 diabetes

byAndrew LeeandKiera Liblik
August 15, 2022
in Cardiology, Chronic Disease, Endocrinology, Pediatrics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Dulaglutide significantly reduced baseline glycated hemoglobin levels as compared to a placebo control in youth with type 2 diabetes (T2DM).

2. Dulaglutide use was not significantly associated with changes in body mass index (BMI), body weight, or height.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Youth with T2DM are known to have more severe insulin resistance and beta cell dysfunction than their adult counterparts. As a result, the number of pharmacological interventions is limited for youth based on their disease severity and higher side effect profile. Dulaglutide, a glucagon-like peptide-1 receptor agonist delivered subcutaneously once weekly may represent an effective intervention for youth with T2DM. In the present study, youth with T2DM were randomized to receive either dulaglutide or a placebo control. The dulaglutide groups had a decreased glycated hemoglobin level at the end of the study, while the placebo group had an increased level. The improvement in the treatment group was seen across subgroups of age, sex, race, ethnic group, diabetes medication use, duration of diabetes, baseline glycated hemoglobin level, BMI, and body weight. Dulaglutide was not superior to placebo with regards to weight, height, or BMI changes. Gastrointestinal events were the most common side effect, which were more common in the treatment group than in the placebo group. In summary, dulaglutide may offer an advantage to other therapeutics due to its effective glycemic control, frequency, and easier method of administration.

Click to read the study in NEJM

Relevant Reading: Long-term complications in youth-onset type 2 diabetes

In-Depth [randomized control trial]: This phase three, randomized, placebo-controlled trial examined the efficacy and safety of dulaglutide in youth with T2DM. The study had a double-blinded period of 26 weeks, followed by 26 weeks of an open-label trial. Youth aged 10 to 17 with a BMI of over the 85th percentile for their height and weight, and glycated hemoglobin between 6.5% and 11% were included. The groups examined were placebo (n=51), 0.75 mg (n=51), and 1.5 mg (n=52) weekly. At 26 weeks, the pooled dulaglutide group had a mean glycated hemoglobin 0.8 percent less than baseline, compared to a 0.6 increase in the placebo group (estimated treatment difference, -1.4%; 95 confidence interval [CI] -1.9 to -0.8; p<0.001). Dulaglutide was also superior to placebo for secondary glycemic endpoints such as a glycated hemoglobin less than 7.0% and change in baseline fasting blood glucose concentration. For those assigned to placebo group and switched to 0.75 mg treatment, a decrease of 0.9% from baseline mean glycated hemoglobin was seen at 13 weeks after they switched (week 39). No clinically relevant changes in body weight, BMI, or height were observed between the treatment and placebo groups. Adverse events were reported in 69% of the placebo group, 75% in the 0.75 mg dulaglutide group, and 73% in the 1.5mg dulaglutide group at the end of 26 weeks. No adverse events led to discontinuation of therapy and no deaths were reported during the 52 weeks of the trial. Overall, dulaglutide may represent a treatment for youth with T2DM, a group with reduced treatment options.

RELATED REPORTS

Gender-affirming hormones improve psychosocial functioning in transgender youth

Left atrial reservoir strain improves ischemic stroke risk prediction in low-risk patients

Online cooking education may improve perceived cooking and motor competencies in children

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cardiologychronic diseasediabetesendocrinologypediatric chronic diseasepediatric endocrinologypediatric medicinepediatricstype 2 diabetesType 2 Diabetes Mellitusyouth diabetes
Previous Post

Cinpanemab therapy does not prevent Parkinson’s disease progression

Next Post

Pediatric asthma morbidity is associated with geographic location and social determinants of health

RelatedReports

Mental health parity law associated with financial protection for children
Endocrinology

Gender-affirming hormones improve psychosocial functioning in transgender youth

January 31, 2023
Intensive rehabilitation not superior to traditional therapy for arm function after stroke
Cardiology

Left atrial reservoir strain improves ischemic stroke risk prediction in low-risk patients

January 31, 2023
Eating in the absence of hunger linked to toddler obesity
Lifestyle

Online cooking education may improve perceived cooking and motor competencies in children

January 31, 2023
Resection of colorectal liver metastases may improve cost and longevity
Chronic Disease

Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease

January 30, 2023
Next Post
Evidence-based interventions for pediatric asthma successfully adapted for community health centers

Pediatric asthma morbidity is associated with geographic location and social determinants of health

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]

Increased use of pediatric CT poses significant oncogenic risk [Classics Series]

Breast cancer chemoprevention may reduce mortality in lobular carcinoma-in-situ

Same appointment mammogram results may result in less stress for patients being screened for breast cancer

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Rocatinlimab may be effective in the treatment of moderate-to-severe atopic dermatitis
  • Gender-affirming hormones improve psychosocial functioning in transgender youth
  • Left atrial reservoir strain improves ischemic stroke risk prediction in low-risk patients
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options